Semaglutide and Muscle Mass: What the STEP Trial Sub-Analyses Actually Show

Every weight-loss intervention — surgical, pharmaceutical, or dietary — takes some of the weight from lean tissue rather than fat. The interesting question is how much. For semaglutide, the answer matters because the drug is increasingly prescribed to populations where preserving muscle is medically important: older adults, post-menopausal women, and people with type 2 diabetes who already have lower baseline lean mass.

The headline number that has been circulating in popular coverage — that 20–40% of weight lost on a GLP-1 receptor agonist is lean body mass — is essentially correct, but it deserves unpacking. The picture is more nuanced than either the “semaglutide melts your muscles” takes or the defensive industry response that “all weight loss looks like this” would suggest. Both can be true at the same time.

What the trials actually measured

STEP 1 was the pivotal phase 3 trial that put semaglutide on the weight-loss map. 1,961 adults with overweight or obesity (and without type 2 diabetes) were randomized 2:1 to weekly subcutaneous semaglutide 2.4 mg or placebo, both layered on top of lifestyle intervention. After 68 weeks, the semaglutide arm had lost a mean of 14.9% of body weight, versus 2.4% in the placebo arm.^[1]

The body-composition picture for GLP-1 receptor agonists comes from several sources. The most directly comparable is the SURMOUNT-1 body-composition sub-study (Look et al., Diabetes Obes Metab 2025), which used DEXA in 160 participants from thetirzepatide pivotal obesity trial. At week 72, the tirzepatide arm lost 21.3% of body weight, with fat mass falling 33.9% and lean mass falling 10.9%. Roughly 75% of the weight lost was fat mass and 25% was lean mass — and the same ~75/25 split was seen in the placebo arm, suggesting the proportional composition of the loss was no different than diet alone.^[2]

A 2025 systematic review and network meta-analysis by Karakasis and colleagues pooled 22 randomized trials of GLP-1 receptor agonists and co-agonists (2,258 participants) and found that across the class, lean mass accounts for approximately 25% of total weight loss. Semaglutide and tirzepatide produced the largest absolute fat loss but were among the least effective at preserving lean mass relative to other agents.^[3]

The qualifier that matters: the proportion of lost weight that comes from lean tissue during GLP-1 therapy is comparable to what you see in unstructured caloric restriction of similar magnitude. The Heymsfield 2024 modeling paper in Obesity, drawing on 897 healthy adults followed longitudinally, estimated that men lose roughly 26% of weight as skeletal muscle during voluntary calorie restriction without exercise, and women roughly 14%. In other words, GLP-1s aren't uniquely catabolic — fast weight loss without resistance training and adequate protein causes lean-mass loss across the board, and GLP-1s simply make fast weight loss possible at scale for the first time.^[4]

How that compares to other weight-loss methods

For context, here's what the literature shows for the share of lost weight that comes from lean mass across several well-studied interventions:

• Bariatric surgery (Roux-en-Y). Roughly 25–30% of total weight lost is lean mass, with significant variation by patient age and post-op activity. The percentage tends to be lower in younger, more active patients.^[6]
• Caloric restriction (general). Modeling across pooled cohorts puts the share at roughly 26% of weight loss as skeletal muscle in men and 14% in women without structured exercise.^[4]
• Very low calorie diets and intermittent fasting. Generally fall in the 20–40% lean-mass range, modified heavily by protein intake and concurrent resistance training.^[7][8]
• Tirzepatide (SURMOUNT-1 sub-study). ~25% lean-mass share over 72 weeks — the same proportional split as the placebo arm of the same trial.^[2][9]

The takeaway: semaglutide isn't catastrophically worse than other major interventions on lean-mass preservation, but it also isn't magically better. The percentages are similar; the difference is that semaglutide produces dramatically more total weight loss in routine clinical use, which means the absolute number of pounds of lean mass lost is larger even when the percentage is normal.

Why this matters more for some patients than others

Not every kilogram of lean mass loss is equal. Lean body mass is an aggregate that includes skeletal muscle, organ tissue, bone mineral, and intracellular water. When weight drops fast, intracellular water shifts can account for a meaningful chunk of early “lean” loss without representing actual muscle atrophy. That's the strongest argument for not panicking about the headline number, and it is the central point of a 2024 JAMA viewpoint by Conte, Hall and Klein arguing that the clinical relevance of GLP-1-induced fat-free mass loss in most adults with obesity has been overstated.^[7][5]

But the patients where the concern is real and not theoretical are:

• Adults over 65. Sarcopenia — age-related muscle loss — starts in the fourth decade and accelerates past 60. An older patient losing 6 kg of lean mass on top of natural sarcopenia can plausibly cross the threshold into functional impairment (slower gait speed, reduced grip strength, higher fall risk).^[10]
• Post-menopausal women. The estrogen drop at menopause already accelerates muscle and bone loss. Layered on top of GLP-1 weight loss without a resistance program, this population shows the largest decrements in DEXA lean mass.
• Patients with sarcopenic obesity at baseline. A subset of obese patients already have low muscle mass relative to their body size before starting any weight-loss program. They're the highest-risk group, and ironically the group most likely to benefit from the metabolic effects of weight loss. Resistance training matters most for them.^[11]
• People with type 2 diabetes. Diabetes itself accelerates muscle loss through insulin resistance and chronic inflammation. The combined effect of diabetes plus rapid weight loss can be larger than either alone.

What the trials show actually preserves lean mass

The good news is that exercise and adequate protein intake during GLP-1 therapy have been studied directly, and the results are encouraging. Several trials have shown that structured exercise during or after GLP-1 receptor agonist therapy preserves more lean body mass than diet or drug alone — Sandsdal and colleagues (Cardiovascular Diabetology, 2023) reported that combining exercise with GLP-1 receptor agonist treatment reduced the severity of adverse body composition changes compared with the drug alone in adults with obesity.^[12]

The interventions that have actually been tested in trials and show meaningful effect:

1. Resistance training, 2–3 sessions per week, progressive overload. Doesn't need to be a gym program — bodyweight protocols and resistance bands have been shown to work in older adults. The dose-response relationship favors heavier loads when tolerable. Volume matters more than session length.
2. Protein intake of 1.2–1.6 g/kg body weight per day. Higher than the standard 0.8 g/kg RDA. For a 75 kg person, that's roughly 90–120 g per day. Spread across meals because GLP-1s slow gastric emptying and you can run into satiety problems trying to hit the target in one sitting.^[13]
3. Maintaining intake even during early appetite suppression. The first 8–12 weeks on semaglutide are when appetite drops fastest. Patients who passively let calorie intake fall to 800–1,000 kcal/day during this window are the ones who show the worst lean-mass outcomes. Forcing protein intake even when not hungry is the single most actionable lever.
4. Vitamin D and creatine. Smaller effects, both well-tolerated, both supported by reasonable trial evidence in older adults losing weight.^[14]

Notice what isn't on the list: branched-chain amino acid supplements, “anabolic” nutraceuticals, leucine powders, or any of the marketing categories sold around GLP-1s. None of these have trial-grade evidence for preserving lean mass during pharmaceutical weight loss.

The clinical bottom line

The fair summary of the evidence: semaglutide produces lean-mass loss in roughly the same proportion as other rapid weight-loss methods, but the absolute amount is larger because the absolute weight loss is larger. For most patients under 60 with normal baseline muscle mass and any kind of physical activity, the clinical significance of the lean-mass loss is small relative to the cardiovascular, metabolic, and quality-of-life benefits of the weight loss itself.

For older patients, post-menopausal women, and anyone with sarcopenic obesity, the picture changes — and the evidence-based response is not to avoid GLP-1s but to layer resistance training and protein intake on top of them. That combination has been studied, and it works.

The thing worth keeping in view: in the SURMOUNT-1 body-composition sub-study, fat mass fell about three times faster than lean mass on tirzepatide, and the proportional ~75/25 split of weight loss into fat versus lean was no different from the placebo arm of the same trial. That's the finding consistent with the cardiovascular and metabolic outcome benefits seen in SELECT and other post-marketing trials of GLP-1 receptor agonists. From a longevity and metabolic-health standpoint, the trade is heavily favorable for almost every patient who would clinically qualify for the drug.^[2]

If you're weighing semaglutide and the muscle-loss concern is what's holding you back, the right question isn't “is this drug catabolic?” It's “am I willing to lift weights twice a week and eat enough protein while I'm on it?” If the answer is yes, the data suggests you'll come out the other side leaner, healthier, and not meaningfully weaker. If the answer is no, the trade is less obviously favorable — and that's a conversation worth having with the prescribing clinician before starting.

Related research

For the broader picture beyond body composition:

• What happens when you stop taking semaglutide — STEP-4, STEP-1 extension, and SURMOUNT-4 on weight regain after discontinuation. Lean mass loss during treatment is one half of the body composition story; weight regain after stopping is the other.
• GLP-1 side effects from the RCT adverse-event tables — including the “Ozempic face” discussion and how it relates to the lean-mass loss documented above.
• What SELECT showed about cardiovascular outcomes — semaglutide's 20% MACE reduction in non-diabetic adults with established CVD, and the finding that the cardiovascular benefit appears largely independent of how much weight patients actually lost.
• Exercise pairing for lean-mass preservation — the resistance-training protocols that the published literature shows mitigate the lean-mass loss documented above.
• What is tai chi walking for weight loss? — companion low-intensity mind-body modality. Tai chi is NOT a primary lean-mass-preservation lever (resistance training has stronger myofibrillar stimulus) but is the strongest evidence-based fall-prevention exercise in the PubMed literature (Sherrington 2019 Cochrane PMID 30703272, high-certainty −20% people-falling endpoint). Particularly relevant for older patients losing weight rapidly on GLP-1 therapy, where transient balance impairment during lean-tissue loss increases fall risk.
• GLP-1 protein calculator — calculates your daily protein target with the GLP-1 bump applied, anchored on the Neeland 2024 lean-mass mitigation review.
• How to calculate macros for weight loss — the four-step Mifflin-St Jeor BMR + FAO/WHO TDEE + Hall 2011 deficit + Morton 2018 protein-floor walkthrough that underwrites the calculator above, with the GLP-1-specific 1.8–2.2 g/kg protein bump from Neeland 2024 and the Mamerow 2014 per-meal distribution rule.
• Best protein powder for weight loss: evidence review — third-party certification criteria (NSF Certified for Sport, USP Verified, Informed Sport), whey vs casein vs plant evidence from the Lim 2021 meta-analysis (PMID 33670701), per-meal dosing per the ISSN 2017 position stand, and protein timing for GLP-1 users hitting 1.6-2.2 g/kg/day.
• Is cottage cheese good for weight loss? — the whole-food casein vehicle for pre-sleep protein delivery, the strongest mitigation lever against the overnight catabolic window that compounds GLP-1 lean-mass loss. Covers Res 2012 (40 g pre-sleep casein increased overnight MPS by ~22%, PMID 22330017), Snijders 2015 (12-wk pre-sleep casein RCT + resistance training, PMID 25926415), and the Leyh/Ormsbee 2018 cottage-cheese-vs- casein-powder equivalence trial (PMID 30249314).
• Are protein shakes good for weight loss? — the powdered + RTD + meal-replacement category that most GLP-1 patients use as the practical bridge to the 1.6–2.2 g/kg/day protein floor when whole-food intake collapses under appetite suppression. Covers the Heymsfield 2003 meal-replacement meta-analysis (PMID 12704397), Astbury 2019 meal-replacement systematic review (PMID 30675990), Wycherley 2012 high-protein- hypocaloric meta-analysis (PMID 23097268), and the Mathai 2017 DIAAS source-quality framework (PMID 28382889).
• Loose skin after GLP-1 weight loss — the downstream consequence of inadequate lean-mass preservation during rapid weight loss.
• How to tighten skin after weight loss naturally — the consumer-action companion: protein and resistance training framework, sustainable rate of loss, smoking cessation and daily SPF, the Ngaage 2020 panniculectomy insurance-coverage criteria, and the risk-score framework for estimating redundancy magnitude.